TYME is developing cancer therapeutics that utilize targeted mechanisms to achieve broad efficacy across various tumor types while maintaining low toxicity profiles. The company aims to provide effective treatment options for patients with diverse cancers, minimizing adverse effects commonly associated with traditional therapies.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to significant toxicity and adverse effects in patients. Many therapies struggle to effectively target diverse tumor types, limiting their overall efficacy and leaving patients with fewer treatment options.
Solution
TYME is developing cancer therapeutics designed to target specific mechanisms within cancer cells, aiming for broad efficacy across various tumor types while minimizing toxicity. Their approach seeks to provide effective treatment options for patients with diverse cancers, reducing the adverse effects commonly associated with traditional therapies. By focusing on targeted mechanisms, TYME aims to improve patient outcomes and quality of life during cancer treatment.
Target Audience
The primary target audience includes patients with diverse cancers and healthcare professionals seeking more effective and less toxic treatment options.
Features
- Targeted mechanisms for cancer cell destruction
- Broad efficacy across various tumor types
- Low toxicity profiles compared to traditional therapies